Evidence-Based Medicine Guidelines
Sublingual immunotherapy for asthma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Sublingual Immunotherapy for Asthma." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/458474/all/Sublingual_immunotherapy_for_asthma.
Sublingual immunotherapy for asthma. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/458474/all/Sublingual_immunotherapy_for_asthma. Accessed November 7, 2024.
Sublingual immunotherapy for asthma. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/458474/all/Sublingual_immunotherapy_for_asthma
Sublingual Immunotherapy for Asthma [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2024 November 07]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/458474/all/Sublingual_immunotherapy_for_asthma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Sublingual immunotherapy for asthma
ID - 458474
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/458474/all/Sublingual_immunotherapy_for_asthma
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
